Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts

被引:45
作者
Mori, T [1 ]
Barrientos, LG
Han, ZZ
Gronenborn, AM
Turpin, JA
Boyd, MR
机构
[1] NCI, Canc Res Ctr, Mol Targets Drug Discovery Program, Frederick, MD 21702 USA
[2] NIDDKD, Phys Chem Lab, NIH, Bethesda, MD 20892 USA
[3] So Res Inst, Infect Dis Res Dept, Frederick, MD 21701 USA
基金
美国国家卫生研究院;
关键词
cyanovirin-N; CV-N; cyanovirins; microbicides; HIV; anti-HIV;
D O I
10.1016/S1046-5928(02)00513-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cyanovirin-N (CV-N) is under development as a topical (vaginal or rectal) microbicide to prevent sexual transmission of human immunodeficiency virus (HIV), and an economically feasible means for very large-scale production of the protein is all urgent priority. We observed that N-glycosylation of CV-N in yeast eliminated the anti-HIV activity, and that dimeric forms and aggregates of CV-N occurred under certain conditions, potentially complicating the efficient large-scale manufacture of pure monomeric CV-N. We therefore expressed and tested CV-N homologs in which the Asn residue at position 30 was replaced with Ala, Gin, or Val, and/or the Pro at position 51 was replaced by Gly to eliminate potential conformational heterogeneity. All homologs exhibited anti-HIV activity comparable to wild-type CV-N and the Pro51Gly homologs were significantly more stable proteins. These glycosylation-resistant, functional cyanovirins should he amenable to large-scale production either in bacteria or in eukaryotic hosts. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 36 条
[1]   The domain-swapped dimer of cyanovirin-N is in a metastable folded state: Reconciliation of X-ray and NMR structures [J].
Barrientos, LG ;
Louis, JM ;
Botos, I ;
Mori, T ;
Han, ZZ ;
O'Keefe, BR ;
Boyd, MR ;
Wlodawer, A ;
Gronenborn, AM .
STRUCTURE, 2002, 10 (05) :673-686
[2]   Solution structure of cyanovirin-N, a potent HIV-inactivating protein [J].
Bewley, CA ;
Gustafson, KR ;
Boyd, MR ;
Covell, DG ;
Bax, A ;
Clore, GM ;
Gronenborn, AM .
NATURE STRUCTURAL BIOLOGY, 1998, 5 (07) :571-578
[3]   Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development [J].
Boyd, MR ;
Gustafson, KR ;
McMahon, JB ;
Shoemaker, RH ;
OKeefe, BR ;
Mori, T ;
Gulakowski, RJ ;
Wu, L ;
Rivera, MI ;
Laurencot, CM ;
Currens, MJ ;
Cardellina, JH ;
Buckheit, RW ;
Nara, PL ;
Pannell, LK ;
Sowder, RC ;
Henderson, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1521-1530
[4]   Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk [J].
Brink, MF ;
Bishop, MD ;
Pieper, FR .
THERIOGENOLOGY, 2000, 53 (01) :139-148
[5]   POTENT AND SPECIFIC-INHIBITION OF HIV ENVELOPE-MEDIATED CELL-FUSION AND VIRUS BINDING BY G-QUARTET-FORMING OLIGONUCLEOTIDE (ISIS-5320) [J].
BUCKHEIT, RW ;
ROBERSON, JL ;
LACKMANSMITH, C ;
WYATT, JR ;
VICKERS, TA ;
ECKER, DJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) :1497-1506
[6]   BIOLOGICAL AND BIOCHEMICAL ANTI-HIV ACTIVITY OF THE BENZOTHIADIAZINE CLASS OF NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
PYLE, CA ;
WHITE, EL ;
BOWDEN, BJ ;
MCMAHON, JB ;
BOYD, MR ;
BADER, JP ;
NICKELL, DG ;
BARTH, H ;
ANTONUCCI, TK .
ANTIVIRAL RESEARCH, 1994, 25 (01) :43-56
[7]   THIAZOLOBENZIMIDAZOLE - BIOLOGICAL AND BIOCHEMICAL ANTIRETROVIRAL ACTIVITY OF A NEW NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR [J].
BUCKHEIT, RW ;
HOLLINGSHEAD, MG ;
GERMANYDECKER, J ;
WHITE, EL ;
MCMAHON, JB ;
ALLEN, LB ;
ROSS, LJ ;
DECKER, WD ;
WESTBROOK, L ;
SHANNON, WM ;
WEISLOW, O ;
BADER, JP ;
BOYD, MR .
ANTIVIRAL RESEARCH, 1993, 21 (03) :247-265
[8]   Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity [J].
Conrad, U ;
Fiedler, U .
PLANT MOLECULAR BIOLOGY, 1998, 38 (1-2) :101-109
[9]   Current evidence and future directions for targeting HIV entry - Therapeutic and prophylactic strategies [J].
D'Souza, MP ;
Cairns, JS ;
Plaeger, SF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02) :215-222
[10]   Plants as bioreactors for protein production: avoiding the problem of transgene silencing [J].
De Wilde, C ;
Van Houdt, H ;
De Buck, S ;
Angenon, G ;
De Jaeger, G ;
Depicker, A .
PLANT MOLECULAR BIOLOGY, 2000, 43 (2-3) :347-359